A Phase I Study of TTI-621 Immunotherapy for Recurrent or Persistent Mycoses Fungoides or Plasmactyoma


Full Title

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides


The purpose of this study is to assess the safety of the investigational drug TTI-621 in patients with recurrent or persistent mycosis fungoides (a type of cutaneous T-cell lymphoma) or plasmacytoma (a type of multiple myeloma). Because TTI-621 is injected directly into a tumor, patients must have tumors that are accessible to a needle inserted through the skin.

TTI-621 targets and blocks a protein called CD47 found on cancer cells. Cancer cells use CD47 like a protective shield to hide from the immune system. Blocking this protein helps the immune system find and destroy the cancer cells.

Patients with mycosis fungoides will receive one or more doses of TTI-621 injected in up to three tumors. Patients with plasmacytoma will receive one or more doses of TTI-621 injected in up to three tumors after they have received radiation therapy.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or persistent mycosis fungoides or plasmacytoma with tumors that can be accessed through the skin.
  • Patients should recover from the serious side effects of previous treatments before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.





Disease Status

Relapsed or Refractory